Celldex Therapeutics, Inc. is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. Our pipeline is built from a proprietary portfolio of antibodies and immunomodulators used alone and in strategic combinations to create novel, disease-specific therapies that induce, enhance or suppress the body's immune response.

View all →   RSSRecent Releases
Apr 27, 2016 Celldex Therapeutics Initiates Phase 1/2 Study of Glembatumumab Vedotin in Squamous Cell Lung Cancer
Apr 20, 2016 Celldex Therapeutics Presents Data Supporting the Clinical Development of Glembatumumab Vedotin and the Preclinical CD40 Program at the AACR Annual Meeting 2016
More →Upcoming Events
Details on upcoming events are not yet available.
Featured Financial Reports
Filing Date Title Type Size
Nov 5, 2015 Form 10-Q View HTML View PDF 330.4 KB Add to Briefcase
Feb 25, 2016 Form 10-K/A View HTML View PDF 1.1 MB Add to Briefcase
Add to Briefcase = add file to Briefcase